Clinical observation of Lingbao Huxindan in treatment of bradycardia arrhythmia
Objective To evaluate the clinical efficacy and safety of Lingbao Huxindan in treatment of bradycardia arrhythmia.Methods Patients(100 cases)with bradycardia arrhythmia in Shanghai Sixth People's Hospital from November 2020 to December 2022 were randomly divided into control(50 cases)and treatment(50 cases)group.Patients in the control group were po administered with Diprophylline Tablets,100 mg/time,three times daily.Patients in the treatment group were po administered with Lingbao Huxindan on the basis of the control group,4 pills/time,three time daily.Patients in two groups were treated for 12 weeks.After treatment,the clinical evaluations were evaluated,the TCM syndrome scores,dynamic electrocardiogram indexes and adverse reactions in two groups before and after treatment were compared.Results After treatment,the clinical effective rate was 97.87%in the treatment group and 91.11%in the control group,the difference between the two groups was statistically significant(P＜0.05).After 4,8 and 12 weeks of treatment,TCM symptom scores in both groups were significantly decreased(P＜0.05).The TCM syndrome scores in the treatment group were lower than those in the control group(P＜0.05).After 4,8 and 12 weeks of treatment,the mean heart rate,total heart rate and minimum heart rate of the two groups were significantly increased(P＜0.05).After 8 and 12 weeks of treatment,the mean heart rate,total heart rate and minimum heart rate in the treatment group were significantly higher than those in the control group(P＜0.05).The total incidence of adverse reactions in the treatment group(2.13%)was significantly lower than that in the control group(11.11%,P＜0.05).Conclusion Lingbao Huxindan has a good curative effect and safety in patients with bradycardia arrhythmias,and its long-term use is better than that of dihydroxypropylline.
NETL
NSTL
万方数据
